VCs Eye Europe's Drug Cabinet: Index, Orion Share Designs on Clinical Stage Compounds
This article was originally published in Start Up
Two new investment vehicles have been formed to take advantage of the relative immaturity of Europe's life sciences industry. Index Ventures and Orion Health Care Equity Partners both see opportunities abound in Europe's biopharmaceutical start-ups, but they have different approaches.
You may also be interested in...
Signs are that Spanish biotech, until now held back by a lack of capital and management expertise, may be about to receive the kick-start it badly needs. Newly-created Ysios Capital Partners is the country's first specialist VC. It's raising a first fund worth €65 million ($92 million)--and it's not alone.
The conventional wisdom is that European biopharma IPOs lag those in the US both in number and average size, held back by fragmented markets, stingy risk-averse investors, and a lack of specialists. The wisdom's changed (or some of it, anyway).
Pfizer's October 2006 acquisition of DNA-vaccine specialist PowderMed was the largest ever acquisition of a UK biotech. PowderMed's investors saw a solid return on the deal, which underscored Big Pharma's rush to spread their bets on next-generation large-molecule platforms.